Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition

NCT02579265 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT02579265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02579265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition
Lead sponsor
Fresenius Kabi
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2015
Completion date
April 10, 2020
Enrollment
204 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hospitalized neonates and infants, expected to require parenteral nutrition for 28 days